| Trial ID: | L1222 |
| Source ID: | NCT04319328
|
| Associated Drug: |
Cefazolin
|
| Title: |
Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hemodialysis Complication|Infectious Disease|End Stage Renal Disease
|
| Interventions: |
DRUG: Cefazolin|DRUG: Ceftazidime
|
| Outcome Measures: |
Primary: Volume of distribution (Vd) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis., 48 to 72 hours|Drug elimination (ke) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis., Drug elimination (ke) during and between dialysis sessions, 48 to 72 hours|Drug clearance (CL) for cefazolin, ceftazidime, and ciprofloxacin in infected patients on chronic intermittent high-flux hemodialysis., 48 to 72 hours |
|
| Sponsor/Collaborators: |
Sponsor: University of Manitoba | Collaborators: The Kidney Foundation of Canada
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
40
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2019-10-18
|
| Completion Date: |
2024-04-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-05-16
|
| Locations: |
Saint Boniface Hospital, Outpatient Hemodialysis Unit, Winnipeg, Manitoba, R2H 2A6, Canada|College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, R3E 0T5, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT04319328
|
